{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:22:21Z","timestamp":1778275341076,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"DOI":"10.7759\/cureus.105392","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:55:36Z","timestamp":1773770136000},"source":"Crossref","is-referenced-by-count":1,"title":["Histologic Features of Melanocytic Nevi Secondary to Melanoma Treatment With Immune Checkpoint Inhibitors"],"prefix":"10.7759","author":[{"given":"Nehaa","family":"Sohail","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaan","family":"Sohail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanaa","family":"Durrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Bilbaoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar  A","family":"Abbud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Reyes Barron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab HO","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017, 8:561. 10.3389\/fphar.2017.00561","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1301a22","article-title":"Regression of multiple melanocytic nevi in two patients on nivolumab for metastatic melanoma","volume":"13","author":"Baeza-Hern\u00e1ndez G","year":"2023","unstructured":"Baeza-Hern\u00e1ndez G, Rubio-Aguilera RF, Garrido-R\u00edos AA, \u00c1lvarez-Garrido H, Mart\u00ednez-Mor\u00e1n C, Borbujo J. Regression of multiple melanocytic nevi in two patients on nivolumab for metastatic melanoma. Dermatol Pract Concept. 2023, 13:10.5826\/dpc.1301a22","journal-title":"Dermatol Pract Concept"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13833","article-title":"Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade","volume":"58","author":"Mauzo SH","year":"2019","unstructured":"Mauzo SH, Tetzlaff MT, Nelson K, et al.. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. Int J Dermatol. 2019, 58:1045-52. 10.1111\/ijd.13833","journal-title":"Int J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10143047","article-title":"Cutaneous events associated with immunotherapy of melanoma: a review","volume":"10","author":"Burzi L","year":"2021","unstructured":"Burzi L, Alessandrini AM, Quaglino P, Piraccini BM, Dika E, Ribero S. Cutaneous events associated with immunotherapy of melanoma: a review. J Clin Med. 2021, 10:10.3390\/jcm10143047","journal-title":"J Clin Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0117-1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study","volume":"4","author":"Koelzer VH","year":"2016","unstructured":"Koelzer VH, Rothschild SI, Zihler D, et al.. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer. 2016, 4:13. 10.1186\/s40425-016-0117-1","journal-title":"J Immunother Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800879","article-title":"Immune checkpoint inhibitor-associated colitis: from mechanism to management","volume":"12","author":"Tang L","year":"2021","unstructured":"Tang L, Wang J, Lin N, Zhou Y, He W, Liu J, Ma X. Immune checkpoint inhibitor-associated colitis: from mechanism to management. Front Immunol. 2021, 12:800879. 10.3389\/fimmu.2021.800879","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.4975","article-title":"Risk factors associated with first and second primary melanomas in a high-incidence population","volume":"159","author":"Olsen CM","year":"2023","unstructured":"Olsen CM, Pandeya N, Dusingize JC, Neale RE, MacGregor S, Law MH, Whiteman DC. Risk factors associated with first and second primary melanomas in a high-incidence population. JAMA Dermatol. 2023, 159:37-46. 10.1001\/jamadermatol.2022.4975","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0615","article-title":"Induction of immune reaction in benign melanocytic nevi without Halo during nivolumab therapy in a patient with melanoma","volume":"153","author":"Nakamura Y","year":"2017","unstructured":"Nakamura Y, Fujino T, Kagamu H, Matsuya T, Teramoto Y, Asami Y, Yamamoto A. Induction of immune reaction in benign melanocytic nevi without Halo during nivolumab therapy in a patient with melanoma. JAMA Dermatol. 2017, 153:832-4. 10.1001\/jamadermatol.2017.0615","journal-title":"JAMA Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0372","article-title":"Understanding and overcoming the inflammatory toxicities of immunotherapy","volume":"8","author":"Dougan M","year":"2020","unstructured":"Dougan M. Understanding and overcoming the inflammatory toxicities of immunotherapy. Cancer Immunol Res. 2020, 8:1230-5. 10.1158\/2326-6066.CIR-20-0372","journal-title":"Cancer Immunol Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-015-0431-9","article-title":"A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma","volume":"10","author":"Uguen A","year":"2015","unstructured":"Uguen A, Talagas M, Costa S, Duigou S, Bouvier S, De Braekeleer M, Marcorelles P. A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma. Diagn Pathol. 2015, 10:195. 10.1186\/s13000-015-0431-9","journal-title":"Diagn Pathol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031582","article-title":"PRAME updated: diagnostic, prognostic, and therapeutic role in skin cancer","volume":"25","author":"Cassalia F","year":"2024","unstructured":"Cassalia F, Danese A, Tudurachi I, et al.. PRAME updated: diagnostic, prognostic, and therapeutic role in skin cancer. Int J Mol Sci. 2024, 25:10.3390\/ijms25031582","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.048","article-title":"Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study","volume":"88","author":"Zhang S","year":"2023","unstructured":"Zhang S, Tang K, Wan G, et al.. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study. J Am Acad Dermatol. 2023, 88:1024-32. 10.1016\/j.jaad.2022.12.048","journal-title":"J Am Acad Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/466950-histologic-features-of-melanocytic-nevi-secondary-to-melanoma-treatment-with-immune-checkpoint-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:55:36Z","timestamp":1773770136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/466950-histologic-features-of-melanocytic-nevi-secondary-to-melanoma-treatment-with-immune-checkpoint-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.105392","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}